- Home
- MDLZ vs REGN Comparison
MDLZ vs REGN Comparison
Compare MDLZ & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDLZ | REGN |
|---|---|---|
| Founded | 2000 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.3B | 68.8B |
| IPO Year | 2001 | 1995 |
Fundamental Metrics
Financial Performance| Metric | MDLZ | REGN |
|---|---|---|
| Price | $62.19 | $799.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 25 |
| Target Price | $66.95 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 6.4M | 588.3K |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.28% | 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | 0.44 | ★ 18.95 |
| Revenue | ★ $38,537,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $4.83 | $12.45 |
| Revenue Next Year | $3.10 | $10.13 |
| P/E Ratio | $141.06 | ★ $42.17 |
| Revenue Growth | 5.75 | ★ 20.82 |
| 52 Week Low | $51.20 | $541.00 |
| 52 Week High | $66.65 | $847.00 |
Technical Indicators
Market Signals| Indicator | MDLZ | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 57.89 |
| Support Level | $60.30 | $732.04 |
| Resistance Level | $62.64 | $818.06 |
| Average True Range (ATR) | 1.03 | 17.86 |
| MACD | -0.22 | -7.08 |
| Stochastic Oscillator | 26.08 | 31.59 |
Price Performance
Historical ComparisonAbout MDLZ Mondelez International Inc.
Mondelez has operated independently since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack enclave with a presence in the biscuit (48% of sales as of the end of fiscal 2025), chocolate (33%), gum/candy (10%), beverage (3%), and cheese and grocery (6%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, and Cadbury. The firm derives around one-third of its revenue from developing markets, around 40% from Europe, and more than one-fourth from North America.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.